Lilly negotiating with telecommunications companies; sells Hybritech monoclonals business.
LILLY PLANNING INVESTMENT IN TELEPHONALS AS IT DIVESTS 39424MONOCLONALS: behind the headlines of its recent Hybritech divestiture, the company is actively in negotiations with major telecommunication and computer firms to support its objective of building a health information network. Although the deals are not directly related, the new focus on telecommunication skills shows the change in synergies between the mid-80's and mid-90's. Lilly Chief Information Officer Tom Trainer discussed the telecommunications negotiations at a Sept. 26 meeting in London at which he described the effort as "aggressive discussions."
You may also be interested in...
Lilly's acquisition of Applied Molecular Evolution will give the company access to technology for optimizing proteins and genes for specific therapeutic targets
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011